Which pharmacologic agents are considered first-line for pharmacologic closure of a hemodynamically significant patent ductus arteriosus (PDA) in preterm neonates, and what are key contraindications?

Prepare for the NCC Board Certification as a Neonatal Nurse Practitioner (NNP-BC) Exam. Access flashcards and multiple-choice questions, complete with hints and explanations. Maximize your readiness for the NNP-BC exam!

Multiple Choice

Which pharmacologic agents are considered first-line for pharmacologic closure of a hemodynamically significant patent ductus arteriosus (PDA) in preterm neonates, and what are key contraindications?

Explanation:
The main idea here is how to medically encourage closure of a hemodynamically significant PDA in a preterm infant. The agents used first are nonsteroidal anti-inflammatory drugs that decrease prostaglandin production, which normally keeps the ductus arteriosus open. Indomethacin and ibuprofen are the typical first-line choices because they reliably promote ductal constriction and closure when given early and appropriately. However, these drugs carry specific risks that define when they should not be used. They are avoided or used with caution if there is active high-grade intraventricular hemorrhage, as rapid closure and fluctuations in cerebral blood flow can worsen CNS bleeding. They are also avoided or used cautiously in substantial renal impairment or oliguria, since these medications can further compromise kidney function. Dense thrombocytopenia increases bleeding risk during therapy, and significant necrotizing enterocolitis signals vulnerability of gut perfusion and potential worsening with NSAID use. Because of these concerns, monitoring is essential—particularly renal function and urine output—to catch adverse effects early. The other options don’t fit as well because they either propose the wrong drugs for first-line use (acetaminophen is considered an alternative in some centers, not the standard first-line agent) or omit important contraindications (ibuprofen alone with no risks overlooks the significant safety considerations).

The main idea here is how to medically encourage closure of a hemodynamically significant PDA in a preterm infant. The agents used first are nonsteroidal anti-inflammatory drugs that decrease prostaglandin production, which normally keeps the ductus arteriosus open. Indomethacin and ibuprofen are the typical first-line choices because they reliably promote ductal constriction and closure when given early and appropriately.

However, these drugs carry specific risks that define when they should not be used. They are avoided or used with caution if there is active high-grade intraventricular hemorrhage, as rapid closure and fluctuations in cerebral blood flow can worsen CNS bleeding. They are also avoided or used cautiously in substantial renal impairment or oliguria, since these medications can further compromise kidney function. Dense thrombocytopenia increases bleeding risk during therapy, and significant necrotizing enterocolitis signals vulnerability of gut perfusion and potential worsening with NSAID use. Because of these concerns, monitoring is essential—particularly renal function and urine output—to catch adverse effects early.

The other options don’t fit as well because they either propose the wrong drugs for first-line use (acetaminophen is considered an alternative in some centers, not the standard first-line agent) or omit important contraindications (ibuprofen alone with no risks overlooks the significant safety considerations).

Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy